| Title | Author(s) | Year | View Count |
 | A Phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2 and VEGFR in advanced hepatocellular carcinoma (HCC) | Yau, T; Yen, CJ; Chen, PJ; Chau, Y; Lencioni, R; Kallender, H; Ottesen, LH; Poon, RTP | 2011 | 231 |
 | Is the treatment of hepatocellular carcinoma on the waiting list necessary? | Majno, P; Lencioni, R; Mornex, F; Girard, N; Poon, RT; Cherqui, D | 2011 | 189 |
| A phase I/II study of Foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2 and VEGFR in advanced hepatocellular carcinoma (HCC) | Yau, TCC; Sukeepaisarnjaroen, W; Chao, Y; Yen, CJ; Lausoontornsiri, W; Chen, PJ; Sanpajit, T; Lencioni, R; Camp, A; Kallender, H; Ottesen, LH; Poon, RTP | 2011 | 67 |
| Treatment before liver transplantation for HCC | Belghiti, J; Carr, BI; Greig, PD; Lencioni, R; Poon, RT | 2008 | 95 |
|
